Trials / Conditions / Neuroendocrine Tumours

Neuroendocrine Tumours

9 registered clinical trials studyying Neuroendocrine Tumours.

Status	Trial	Sponsor	Phase
Terminated	Open-Label Surufatinib in European Patients With NET NCT04579679	Hutchmed	Phase 2
Completed	A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers NCT02923934	Olivia Newton-John Cancer Research Institute	Phase 2
Completed	Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neu NCT02698410	Ipsen	Phase 2
Terminated	A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumour NCT02788578	Ipsen	—
Completed	Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients NCT02075606	Ipsen	Phase 4
Completed	68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours NCT01673906	Azienda USL Reggio Emilia - IRCCS	Phase 2
Completed	Somatuline Predictive Factors in Acromegaly and NET NCT01840449	Ipsen	—
Terminated	[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and NCT00323076	AHS Cancer Control Alberta	Phase 1 / Phase 2
Completed	Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine NCT00326469	Ipsen	Phase 2